ELTX net incomeQ3 2026-$7.98M
ELTX net income was -$7.98M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$10.08M a year earlier. For the full fiscal 2025 it was -$39.57M, compared with -$51.90M in fiscal 2024.
Elicio Therapeutics Inc. (ELTX) financials
For the twelve months ended Sep 30, 2026, Elicio Therapeutics Inc. reported -$35.74M of net income.
- Net income, TTM
- -$35.74M
- Cash
- $30.90M
- Total debt
- $9.63M
- Market cap
- $40.8M
FY2020FY2022
FY2020FY2025
FY2020FY2025
ELTX revenue and earnings growth
ELTX EPSQ3 2026-$0.30
ELTX diluted EPS was -$0.30 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$2.58, compared with -$4.25 in fiscal 2024.
ELTX free cash flowQ4 2025-$6.81M
ELTX free cash flow was -$6.81M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$8.79M a year earlier. For the full fiscal 2025 it was -$36.97M, compared with -$37.16M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $2.30M | $28.31M | $2.88M |
| Cost of revenue | - | - | - | $0 | $433.0K | $1.19M |
| Gross profit | - | - | - | $2.30M | $27.88M | $1.69M |
| Research and development | $24.90M | $33.66M | $23.85M | $18.10M | $48.70M | $38.98M |
| Selling, general and admin | $12.81M | $11.33M | $11.90M | $5.63M | $18.49M | $17.99M |
| Operating income | -$37.71M | -$44.99M | -$35.74M | -$23.73M | -$39.31M | -$55.27M |
| Interest expense | $1.13M | $455.0K | $1.06M | $3.60M | - | - |
| Pre-tax income | -$39.57M | -$51.90M | - | -$38.80M | -$54.57M | -$80.11M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.57M | -$51.90M | -$35.20M | -$28.21M | -$54.57M | -$80.11M |
| EPS, basic | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$1.93 | -$5.43 |
| EPS, diluted | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$1.93 | -$5.43 |
| Diluted shares | 15.3M | 12.2M | 5.1M | 315,998 | 28.2M | 14.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $18.56M | $19.49M | $14.30M | $8.41M | $10.04M | $34.61M |
| Receivables | - | - | - | $0 | - | - |
| Current assets | $19.31M | $20.69M | $16.35M | $10.72M | $91.25M | $42.30M |
| Total assets | $25.86M | $28.18M | $27.15M | $22.66M | $96.51M | $47.35M |
| Current liabilities | $8.11M | $11.52M | $9.76M | $6.87M | $11.30M | $107.45M |
| Short-term debt | $0 | - | - | - | - | - |
| Long-term debt | $9.41M | $20.03M | $0 | - | $0 | $635.0K |
| Total debt | $9.41M | $20.03M | $0 | - | $0 | $635.0K |
| Total liabilities | $24.23M | $39.49M | $15.77M | $13.75M | $15.01M | $137.80M |
| Shareholders' equity | $1.64M | -$11.31M | $11.37M | -$102.14M | -$74.54M | -$90.45M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$36.95M | -$37.07M | -$32.69M | -$22.18M | -$52.64M | -$22.89M |
| Capital expenditures | $16.0K | $87.0K | $66.0K | $654.0K | $382.0K | $41.0K |
| Free cash flow | -$36.97M | -$37.16M | -$32.76M | -$22.83M | -$53.02M | -$22.93M |
| Investing cash flow | -$16.0K | -$84.0K | -$32.0K | -$654.0K | -$382.0K | -$41.0K |
| Financing cash flow | $36.70M | $42.32M | $38.61M | $21.20M | $107.17M | $52.41M |
| Stock-based compensation | $2.70M | $1.45M | $1.18M | $579.0K | $12.04M | $4.72M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -91.9% | 883.1% | - |
| Gross margin | - | - | - | 100.0% | 98.5% | 58.7% |
| Operating margin | - | - | - | -1031.4% | -138.8% | -1919.2% |
| Net margin | - | - | - | -1225.9% | -192.8% | -2781.5% |
| Free cash flow margin | - | - | - | -992.3% | -187.3% | -796.1% |
| Return on equity | -2418.8% | - | -309.5% | - | - | - |
| Return on assets | -153.0% | -184.2% | -129.7% | -124.5% | -56.5% | -169.2% |
| Current ratio | 2.38 | 1.80 | 1.68 | 1.56 | 8.08 | 0.39 |
| Debt to equity | 5.75 | - | 0.00 | - | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $4.89M | $6.81M | $6.76M | $5.08M | $5.04M | $7.01M | $7.78M | $10.71M | $7.21M | $8.18M | $7.56M | $6.16M |
| Selling, general and admin | $3.56M | $3.62M | $3.85M | $3.76M | $3.01M | $3.08M | $2.96M | $2.77M | $3.14M | $2.74M | $2.68M | $3.23M |
| Operating income | -$8.45M | -$10.43M | -$10.60M | -$8.84M | -$8.04M | -$10.09M | -$10.74M | -$13.48M | -$10.34M | -$10.92M | -$10.24M | -$9.39M |
| Interest expense | $413.0K | $410.0K | $407.0K | $337.0K | $426.0K | $194.0K | $176.0K | $234.0K | $137.0K | $49.0K | $36.0K | $2.0K |
| Pre-tax income | -$7.92M | - | - | -$7.72M | -$10.08M | - | - | - | - | - | - | - |
| Income tax | $55.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.98M | -$8.22M | -$11.82M | -$7.72M | -$10.08M | -$10.56M | -$11.21M | -$14.00M | -$18.84M | -$7.23M | -$11.83M | -$8.95M |
| EPS, basic | -$0.30 | -$0.43 | -$0.65 | - | -$0.60 | -$0.66 | -$0.87 | - | -$1.39 | -$0.64 | -$1.15 | - |
| EPS, diluted | -$0.30 | -$0.43 | -$0.65 | - | -$0.60 | -$0.66 | -$0.87 | - | -$1.39 | -$0.64 | -$1.15 | - |
| Diluted shares | 26.3M | 19.2M | 18.2M | - | 16.7M | 16.1M | 13.0M | - | 13.6M | 11.3M | 10.3M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.90M | $23.48M | $14.95M | $18.56M | $20.61M | $22.09M | $18.35M | $19.49M | $26.02M | $3.42M | $11.85M | $14.30M |
| Current assets | $34.03M | $25.48M | $16.20M | $19.31M | $21.46M | $22.60M | $20.93M | $20.69M | $30.65M | $6.69M | $14.13M | $16.35M |
| Total assets | $39.60M | $31.33M | $22.69M | $25.86M | $28.28M | $29.53M | $28.14M | $28.18M | $38.39M | $15.75M | $24.48M | $27.15M |
| Current liabilities | $9.93M | $9.20M | $7.23M | $8.11M | $6.51M | $9.92M | $11.41M | $11.52M | $9.02M | $7.58M | $5.95M | $9.76M |
| Short-term debt | $2.48M | - | - | $0 | - | - | - | - | - | - | - | - |
| Long-term debt | $7.16M | $9.54M | $9.47M | $9.41M | $9.72M | $9.34M | $0 | $20.03M | - | - | - | $0 |
| Total debt | $9.63M | $9.54M | $9.47M | $9.41M | $9.72M | $9.34M | $0 | $20.03M | - | - | - | $0 |
| Total liabilities | $20.75M | $23.39M | $24.13M | $24.23M | $24.47M | $27.69M | $19.24M | $39.49M | $57.37M | $17.40M | $19.61M | $15.77M |
| Shareholders' equity | $18.85M | $7.94M | -$1.44M | $1.64M | $3.82M | $1.83M | $8.90M | -$11.31M | -$18.99M | -$1.65M | $4.87M | $11.37M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.36M | -$8.16M | -$11.64M | -$6.80M | -$11.09M | -$8.95M | -$10.12M | -$8.74M | -$7.27M | -$8.93M | -$12.12M | -$9.89M |
| Capital expenditures | - | - | - | $16.0K | $0 | - | - | $45.0K | $0 | $42.0K | $0 | $0 |
| Free cash flow | - | - | - | -$6.81M | -$11.09M | - | - | -$8.79M | -$7.27M | -$8.97M | -$12.12M | -$9.89M |
| Investing cash flow | - | - | - | -$16.0K | $0 | $0 | $0 | -$45.0K | $0 | -$42.0K | $3.0K | $0 |
| Financing cash flow | $17.79M | $16.51M | $8.03M | $4.86M | $9.57M | $11.93M | $10.33M | $227.0K | $30.75M | $316.0K | $11.02M | $7.00M |
| Stock-based compensation | $1.11M | $935.0K | $868.0K | $772.0K | $698.0K | $710.0K | $517.0K | $464.0K | $314.0K | $350.0K | $324.0K | $337.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.43 | 2.77 | 2.24 | 2.38 | 3.29 | 2.28 | 1.83 | 1.80 | 3.40 | 0.88 | 2.37 | 1.68 |
| Debt to equity | 0.51 | 1.20 | - | 5.75 | 2.55 | 5.09 | 0.00 | - | - | - | - | 0.00 |
Source: XBRL data Elicio Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ELTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ELTX | - | - | -$35.74M | - | $40.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
ELTX FAQ
4 questionsIs ELTX profitable?
No. Elicio Therapeutics Inc. reported a net loss of $35.74M for the twelve months ended Sep 30, 2026.How much cash and debt does ELTX have?
Elicio Therapeutics Inc. reported $30.90M in cash and cash equivalents and $9.63M of debt on its most recent balance sheet in SEC filings.When did ELTX last report financial results?
The latest statements here come from Elicio Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this ELTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Elicio Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.